Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)
RecruitingNCT04197921Phase: NAStarted 2019-11-27
Summary
The purpose of this clinical trial is to investigate Low Intensity Focused Ultrasound (LIFU) using the Exablate® Model 4000 Type 2.0/2.1 as an adjunctive neuromodulatory treatment for OUD (Opioid Use
Eligibility
Sex
ALL
Min Age
18 Years
Max Age
60 Years
Locations
Tampa General HospitalTampa, Florida, United States
University of Maryland, BaltimoreBaltimore, Maryland, United States
Weill Cornell MedicineNew York, New York, United States
West Virginia University: Rockefeller Neuroscience InstituteMorgantown, West Virginia, United States
View full study details on ClinicalTrials.gov
clinicaltrials.gov/study/NCT04197921